Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.

Journal of experimental & clinical cancer research : CR - 18 Jun 2018

Farina Antonietta Rosella, Cappabianca Lucia, Ruggeri Pierdomenico, Gneo Luciana, Pellegrini Cristina, Fargnoli Maria-Concetta, Mackay Andrew Reay

Abstract excerpt

Oncogenes derived from the neurotrophin receptor tropomyosin-related kinase TrkA act as drivers in sub-populations of a wide-range of human cancers. This, combined with a recent report that both adult and childhood cancers driven by novel oncogenic TrkA chimeric-fusions exhibit profound, long-lived therapeutic responses to the Trk inhibitor Larotrectinib, highlights the need to improve clinical detection of TrkA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Alternative Splicing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to Genomic Instability

Share to Oncogene Proteins

Share to Receptor, trkA

Share to Stress, Physiological

Share to Unfolded Protein Response

Source

Open in PubMed Open full text

Identifiers

PMID: 29914559
DOI: 10.1186/s13046-018-0786-3
PMCID: PMC6006588

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.PMID 29914559Read ↗

TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance.Semantic proximity Read ↗

NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesSemantic proximity Read ↗

A review of NTRK fusions in cancerSemantic proximity Read ↗

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy TargetSemantic proximity Read ↗

Alternative TrkAIII Splicing: A Potential Regulated Tumor-Promoting Switch and Therapeutic Target in NeuroblastomaSemantic proximity Read ↗

Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumoursSemantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

Oncogenic role of a developmentally regulated <i>NTRK2</i> splice variantSemantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Testing algorithm for identification of patients with TRK fusion cancerSemantic proximity Read ↗

TRKing down an old oncogene in a new era of targeted therapy.Semantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.